Exyte has completed the integration of Pharmaplan into its biopharma and life sciences division, creating a unified engineering platform for the design and delivery of GMP facilities across Europe.
The merger brings Pharmaplan’s specialist teams and locations under the Exyte banner, combining decades of life-sciences expertise with global engineering and construction capacity.
“Bringing Pharmaplan fully into Exyte combines global delivery scale with five decades of life‑sciences process and GMP expertise,” said Dr Wolfgang Büchele, CEO of Exyte.
Exyte first announced the acquisition in September 2024 as part of a strategy to deepen engagement with rapidly growing biotech and pharmaceutical markets across Europe.
The integration strengthens Exyte’s ability to respond to rising demand for rapid-to-market, compliant facilities, including advanced therapies and cell and gene therapy production spaces.
Changes since the merger
Since the merger announcement, the integrated teams have worked to align systems, standards and best practices.
According to Exyte, existing projects continued without disruption and customer relationships were preserved and strengthened throughout the transition.
Market response has been positive, with the combined business reporting major project wins and a strong order intake in 2025.
With Pharmaplan now fully embedded, Exyte offers biopharmaceutical clients a comprehensive suite of services across the life cycle of facility development.
The combined organisation offers end-to-end services, from concept and detailed engineering through construction, commissioning, qualification and validation (CQV), for a range of pharmaceutical manufacturing projects.
The services incorporate digital integration, including model-based design, 3D/4D planning, digital QA/QC workflows and AI-supported decision tools.
Exyte now operates from more than 40 locations across 12 European countries, with the integrated business also supporting projects in Southeast Asia.